Since our previous study has demonstrated that the MUC4 promoter has STAT1 binding sites and regulates MUC4 expression in pancreatic cancer cells [33], we investigated whether the levels of phosphorylated STAT1 could influence MUC4 in pancreatic cancer cells treated with the pan-EGFR inhibitors. Here, STAT1 is linked to pancreatic neoplasm.